InvestSMART

Vitrafy Life Sciences Limited (ASX: VFY) - Announcements

Current share price for VFY : $3.120 0.17 (5.76%)+

ASX company news and announcements for Vitrafy Life Sciences Limited (VFY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Vitrafy Life Sciences Limited (VFY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Vitrafy Life Sciences Limited (VFY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Vitrafy Life Sciences Limited (VFY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$192 Vitrafy Share Purchase Plan Opens - SPP Offer Booklet 19 Jun 2026 8:20AM $2.760 $3.120 risen by 13.04%
$192 Cleansing Notice 18 Jun 2026 8:22AM $2.800 $3.120 risen by 11.43%
$192 Application for quotation of securities - VFY 18 Jun 2026 8:22AM $2.800 $3.120 risen by 11.43%
$192 Proposed issue of securities - VFY 12 Jun 2026 9:33AM $3.800 $3.120 fallen by 17.89%
$192 Vitrafy Equity Raising Presentation 12 Jun 2026 9:33AM $3.800 $3.120 fallen by 17.89%
$192 Vitrafy Placement Completion and SPP Announcement 12 Jun 2026 9:32AM $3.800 $3.120 fallen by 17.89%
$192 Trading Halt 10 Jun 2026 8:32AM $3.800 $3.120 fallen by 17.89%
$192 Vitrafy Investor Presentation 3 Jun 2026 8:20AM $2.790 $3.120 risen by 11.83%
$192 Vitrafy enters a partnership with Vitalant Innovation Center 2 Jun 2026 10:08AM $2.660 $3.120 risen by 17.29%
$192 Phase 2 USAISR Platelet Results Investor Briefing 22 May 2026 8:23AM $2.340 $3.120 risen by 33.33%
$192 Phase 2 USAISR Platelet Results Investor Presentation 22 May 2026 8:23AM $2.340 $3.120 risen by 33.33%
$192 Final US Army Phase 2 Platelet Results 22 May 2026 8:20AM $2.340 $3.120 risen by 33.33%
$192 Quarterly Investor Briefing Presentation 28 Apr 2026 8:22AM $1.990 $3.120 risen by 56.78%
$192 Q3 FY26 Quarterly Activities Report and Appendix 4C 28 Apr 2026 8:21AM $1.990 $3.120 risen by 56.78%
$192 Vitrafy Q3 FY26 Investor Briefing 23 Apr 2026 4:27PM $1.895 $3.120 risen by 64.64%
$192 USAISR Completes Phase 2 Platelet Study 8 Apr 2026 8:23AM $1.730 $3.120 risen by 80.35%
$192 NWR Virtual Healthcare Conference Presentation 26 Mar 2026 8:14AM $1.680 $3.120 risen by 85.71%
$192 Vitrafy to present at NWR Virtual Healthcare Conference 24 Mar 2026 5:40PM $1.650 $3.120 risen by 89.09%
$192 Change of Director's Interest Notice 19 Feb 2026 11:09AM $1.710 $3.120 risen by 82.46%
$192 FY26 Half Year Results Presentation 4 Feb 2026 8:25AM $1.650 $3.120 risen by 89.09%
$192 FY26 Appendix 4D and Half Year Report 4 Feb 2026 8:25AM $1.650 $3.120 risen by 89.09%
$192 Vitrafy FY26 Half Year Investor Briefing 3 Feb 2026 8:18AM $1.650 $3.120 risen by 89.09%
$192 Quarterly Investor Briefing Presentation 29 Jan 2026 8:17AM $1.855 $3.120 risen by 68.19%
$192 Q2 FY26 Quarterly Activities Report and Appendix 4C 29 Jan 2026 8:17AM $1.855 $3.120 risen by 68.19%
$192 Vitrafy Q2 FY26 Investor Briefing 28 Jan 2026 2:22PM $1.800 $3.120 risen by 73.33%

1 - 25 of 102 results

Page 1 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.